60 Degrees Pharmaceuticals Inc
SXTP
Company Profile
Business description
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.
Contact
1025 Connecticut Avenue NW
Suite 1000
Washington, D.CWA20036
USAT: +1 202 327-5422
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
2
Stocks News & Analysis
stocks
Are investors missing the boat on this future ASX leader?
The market is underestimating the clear path to profitability.
stocks
ASX shares plunge but remain undervalued
Shares drop 17% after guidance is revised but we still see value.
stocks
Ask the analyst: Why have markets shunned APA Group?
Australia's premier gas infrastructure firm used to be a market darling, but its shares have taken a severe de-rating in recent years.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,494.30 | 22.50 | 0.27% |
| CAC 40 | 7,423.67 | 15.03 | 0.20% |
| DAX 40 | 20,271.33 | 138.48 | 0.69% |
| Dow JONES (US) | 42,518.28 | 221.16 | 0.52% |
| FTSE 100 | 8,201.54 | 22.65 | -0.28% |
| HKSE | 19,219.78 | 345.64 | 1.83% |
| NASDAQ | 19,044.39 | 43.71 | -0.23% |
| Nikkei 225 | 38,474.30 | 716.10 | -1.83% |
| NZX 50 Index | 12,902.69 | 18.31 | 0.14% |
| S&P 500 | 5,842.91 | 6.69 | 0.11% |
| S&P/ASX 200 | 8,251.80 | 20.80 | 0.25% |
| SSE Composite Index | 3,240.94 | 80.19 | 2.54% |